These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 33655218)

  • 1. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.
    Cavalli G; Larcher A; Tomelleri A; Campochiaro C; Della-Torre E; De Luca G; Farina N; Boffini N; Ruggeri A; Poli A; Scarpellini P; Rovere-Querini P; Tresoldi M; Salonia A; Montorsi F; Landoni G; Castagna A; Ciceri F; Zangrillo A; Dagna L
    Lancet Rheumatol; 2021 Apr; 3(4):e253-e261. PubMed ID: 33655218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.
    Cavalli G; De Luca G; Campochiaro C; Della-Torre E; Ripa M; Canetti D; Oltolini C; Castiglioni B; Tassan Din C; Boffini N; Tomelleri A; Farina N; Ruggeri A; Rovere-Querini P; Di Lucca G; Martinenghi S; Scotti R; Tresoldi M; Ciceri F; Landoni G; Zangrillo A; Scarpellini P; Dagna L
    Lancet Rheumatol; 2020 Jun; 2(6):e325-e331. PubMed ID: 32501454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy of COVID-19: Inside and Beyond IL-6 Signalling.
    Zizzo G; Tamburello A; Castelnovo L; Laria A; Mumoli N; Faggioli PM; Stefani I; Mazzone A
    Front Immunol; 2022; 13():795315. PubMed ID: 35340805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID): A structured summary of a study protocol for a randomised controlled trial.
    Maes B; Bosteels C; De Leeuw E; Declercq J; Van Damme K; Delporte A; Demeyere B; Vermeersch S; Vuylsteke M; Willaert J; Bollé L; Vanbiervliet Y; Decuypere J; Libeer F; Vandecasteele S; Peene I; Lambrecht B
    Trials; 2020 Jun; 21(1):468. PubMed ID: 32493441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study.
    Küçükşahin O; Erden A; Karakaş Ö; Güven SC; Armağan B; Şahiner EŞ; İnan O; Kurtipek AC; Gemcioğlu E; Karaahmetoğlu S; Turan S; İzdeş S; Erdem D; Aypak A; Ayhan M; Akıncı E; Bodur H; Güner R; Omma A; Ateş İ
    Turk J Med Sci; 2022 Oct; 52(5):1486-1494. PubMed ID: 36422492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anakinra on mortality in patients with COVID-19: a systematic review and patient-level meta-analysis.
    Kyriazopoulou E; Huet T; Cavalli G; Gori A; Kyprianou M; Pickkers P; Eugen-Olsen J; Clerici M; Veas F; Chatellier G; Kaplanski G; Netea MG; Pontali E; Gattorno M; Cauchois R; Kooistra E; Kox M; Bandera A; Beaussier H; Mangioni D; Dagna L; van der Meer JWM; Giamarellos-Bourboulis EJ; Hayem G;
    Lancet Rheumatol; 2021 Oct; 3(10):e690-e697. PubMed ID: 34396156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study.
    Hsu TY; D'Silva KM; Patel NJ; Wang J; Mueller AA; Fu X; Prisco L; Martin L; Vanni KMM; Zaccardelli A; Cook C; Choi HK; Zhang Y; Gravallese EM; Wallace ZS; Sparks JA
    Lancet Rheumatol; 2021 Sep; 3(9):e638-e647. PubMed ID: 34095857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
    Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
    Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anakinra for severe forms of COVID-19: a cohort study.
    Huet T; Beaussier H; Voisin O; Jouveshomme S; Dauriat G; Lazareth I; Sacco E; Naccache JM; Bézie Y; Laplanche S; Le Berre A; Le Pavec J; Salmeron S; Emmerich J; Mourad JJ; Chatellier G; Hayem G
    Lancet Rheumatol; 2020 Jul; 2(7):e393-e400. PubMed ID: 32835245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study.
    Webb BJ; Peltan ID; Jensen P; Hoda D; Hunter B; Silver A; Starr N; Buckel W; Grisel N; Hummel E; Snow G; Morris D; Stenehjem E; Srivastava R; Brown SM
    Lancet Rheumatol; 2020 Dec; 2(12):e754-e763. PubMed ID: 33015645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the effectiveness of different doses of tocilizumab and sarilumab in the treatment of severe COVID-19: a natural experiment due to drug shortages.
    Swets MC; Moss RJ; Kor F; Hilarius D; Moes DJAR; Berkhout WE; van den Toorn LM; van den Oever NCG; de Valk R; Rosendaal FR; Hunfeld N; Groeneveld GH; de Boer MGJ
    Int J Infect Dis; 2023 Apr; 129():57-62. PubMed ID: 36738957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GM-CSF blockade with mavrilimumab in severe COVID-19 pneumonia and systemic hyperinflammation: a single-centre, prospective cohort study.
    De Luca G; Cavalli G; Campochiaro C; Della-Torre E; Angelillo P; Tomelleri A; Boffini N; Tentori S; Mette F; Farina N; Rovere-Querini P; Ruggeri A; D'Aliberti T; Scarpellini P; Landoni G; De Cobelli F; Paolini JF; Zangrillo A; Tresoldi M; Trapnell BC; Ciceri F; Dagna L
    Lancet Rheumatol; 2020 Aug; 2(8):e465-e473. PubMed ID: 32835256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study.
    Biran N; Ip A; Ahn J; Go RC; Wang S; Mathura S; Sinclaire BA; Bednarz U; Marafelias M; Hansen E; Siegel DS; Goy AH; Pecora AL; Sawczuk IS; Koniaris LS; Simwenyi M; Varga DW; Tank LK; Stein AA; Allusson V; Lin GS; Oser WF; Tuma RA; Reichman J; Brusco L; Carpenter KL; Costanzo EJ; Vivona V; Goldberg SL
    Lancet Rheumatol; 2020 Oct; 2(10):e603-e612. PubMed ID: 32838323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tocilizumab in patients with severe COVID-19: a retrospective cohort study.
    Guaraldi G; Meschiari M; Cozzi-Lepri A; Milic J; Tonelli R; Menozzi M; Franceschini E; Cuomo G; Orlando G; Borghi V; Santoro A; Di Gaetano M; Puzzolante C; Carli F; Bedini A; Corradi L; Fantini R; Castaniere I; Tabbì L; Girardis M; Tedeschi S; Giannella M; Bartoletti M; Pascale R; Dolci G; Brugioni L; Pietrangelo A; Cossarizza A; Pea F; Clini E; Salvarani C; Massari M; Viale PL; Mussini C
    Lancet Rheumatol; 2020 Aug; 2(8):e474-e484. PubMed ID: 32835257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sarilumab plus standard of care
    Mastrorosa I; Gagliardini R; Segala FV; Mondi A; Lorenzini P; Cerva C; Taddei E; Bai F; Vergori A; Marcantonio N; Pinnetti C; Cicalini S; Murri R; Mazzotta V; Camici M; Mosti S; Bini T; Maffongelli G; Beccacece A; Milozzi E; Iannetta M; Lamonica S; Fusto M; Plazzi MM; Ottou S; Lichtner M; Fantoni M; Andreoni M; Sarmati L; Cauda R; Girardi E; Nicastri E; D'Arminio Monforte A; Palmieri F; Cingolani A; Vaia F; Antinori A;
    EClinicalMedicine; 2023 Mar; 57():101895. PubMed ID: 36936403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of anticytokine treatments added to corticosteroids in patients with COVID-19-associated pneumonia and hyperinflammation: a single center experience.
    Yildirim F; Erdogan M; Mutlu MY; Icacan OC; Onar MI; Bes C
    Eur Rev Med Pharmacol Sci; 2022 Oct; 26(19):7297-7304. PubMed ID: 36263542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study.
    Manson JJ; Crooks C; Naja M; Ledlie A; Goulden B; Liddle T; Khan E; Mehta P; Martin-Gutierrez L; Waddington KE; Robinson GA; Ribeiro Santos L; McLoughlin E; Snell A; Adeney C; Schim van der Loeff I; Baker KF; Duncan CJA; Hanrath AT; Lendrem BC; De Soyza A; Peng J; J'Bari H; Greenwood M; Hawkins E; Peckham H; Marks M; Rampling T; Luintel A; Williams B; Brown M; Singer M; West J; Jury EC; Collin M; Tattersall RS
    Lancet Rheumatol; 2020 Oct; 2(10):e594-e602. PubMed ID: 32864628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation.
    Potere N; Di Nisio M; Rizzo G; La Vella M; Polilli E; Agostinone A; Spacone A; Di Carlo S; Costantini A; Abbate A; Porreca E; Parruti G
    Int J Infect Dis; 2020 Nov; 100():421-424. PubMed ID: 32768701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.